Study of BHV-1300 in Graves' Disease

Part of paid clinical trials in South Gate, California.

Sponsor
Biohaven Therapeutics Ltd.
Study ID
NCT06980649
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 65 Years
Healthy Volunteers
Not accepted

Interventions

  • BHV-1300 — DRUG
    BHV-1300 is delivered subcutaneously (SC)

Study Details

The purpose of this study is to determine if BHV-1300 is a safe treatment in participants with Graves' Disease and to explore its effect on disease-specific biomarkers.

Key Dates

Start date
Aug 21, 2025
Status verified
May 2026
Primary completion
Sep 30, 2027
Completion
Sep 30, 2027

Study Design

Enrollment
15 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: BHV-1300

Primary Outcome Measure

Number of participants with Serious AEs (SAEs), AEs leading to discontinuation, deaths [ Time Frame: Baseline to Week 52 ]

Central Contacts

Locations (10)

FacilityCityStateZIPSite coordinators
Site-103South GateCalifornia90280-
Site-100MiamiFlorida33126-
Site-104ColumbusGeorgia31904-
Site-108GreenvilleNorth Carolina27834-
Site-110CantonOhio44718-
Site-107MemphisTennessee38119-
Site-109DallasTexas75246-
Site-101HoustonTexas77095-
Site-106HoustonTexas77054-
Site-105Shavano ParkTexas78231-

Find similar trials in South Gate, CA

By research site
Site-103· South Gate, CASite-100· Miami, FLSite-104· Columbus, GASite-108· Greenville, NCSite-110· Canton, OHSite-107· Memphis, TN

Related Studies